Recently published undercover videos show multiple scientists working for pharmaceutical giant Pfizer, confirm that people who are naturally infected with COVID-19 have a far superior immunity to the virus than the immunity the vaccines allegedly provide.
Nick Karl, a scientist who is directly involved in the production of Pfizer’s COVID vaccine, said that natural immunity is more effective than the current COVID-19 vaccines, including the one produced by the company he works for.
“When somebody is naturally immune — like they got COVID — they probably have more antibodies against the virus…When you actually get the virus, you’re going to start producing antibodies against multiple pieces of the virus…So, your antibodies are probably better at that point than the [COVID] vaccination,” Karl said.
A second Pfizer official and Senior Associate Scientist, Chris Croce, corroborated Karl’s assertion about COVID immunity, and a third Pfizer scientist, Rahul Khandke, admitted his company demands that its employees keep this information from the public.
Watch the video clip below:
A recent scientific paper published in Nature offers a more comprehensive estimate that places the true number of infections by the end of 2020 at more than 100 million people. That’s equal to almost one third of the U.S. population. This revised number shows just how rapidly the novel coronavirus spread through the country last year.
If this estimate is accurate, it is safe to assume that the more transmissible delta variant which became dominant this year, may have already infected around 100 million more Americans in 2021.
This would mean that almost 75% of the population already have a natural immunity to the virus, not counting those who were vaccinated. The numbers would also mean that the overall infection fatality rate is far lower than previously believed.
Researchers from Washington University in St. Louis also reported last month that 11 months after a mild infection immune cells were still capable of producing protective antibodies. The authors concluded that prior Covid infection induces a “robust” and “long-lived humoral immune response,” leading some scientists to suggest that natural immunity is probably lifelong.
Another recent study found that the current vaccines do next to nothing to help the body’s CD8 T-cells, which is the key to long-term immunity.
The CEO of Pfizer, Albert Bourla, when asked about when he foresaw the end of the pandemic, said that he does not see life going back to normal without regular vaccinations.
According to the first-quarter results published by Pfizer this week, its coronavirus jab has racked up billions for the biopharma giant in the first three months of 2021.
The financial results also revealed that Pfizer has vastly exceeded its Covid-19 vaccine sales forecast of $15bn, and now expects the jab to bring in over $30bn of revenue in 2021 – an increase of 73% on previously anticipated figures.
According to a recent report, Pfizer is planning on recommending their new twice-per-day COVID pill the company is developing alongside their proprietary vaccines.
“Success against COVID-19 will likely require both vaccines & treatments,” Pfizer CEO Albert Bourla said on Twitter recently. “We’re pleased to share we’ve started a Phase 2/3 study of our oral antiviral candidate-specifically designed to combat SARS-CoV-2-in non-hospitalized, low-risk adults.”
Two COVID-19 antiviral pills are now in Phase 3 trials and are bringing claims by the national and international media that a proven oral treatment will soon be available to quell the SARS-CoV-2 infection.
Pfizer’s PF-07321332, in combination with the HIV antiviral ritonavir, has begun Phase 2/3 testing as a treatment for people who are infected with SARS-CoV-2 but who are less likely to be hospitalized with COVID-19.
Merck & Co. with partner Ridgeback Biotherapeutics is well into a Phase 3 trial of molnupiravir as a treatment for people who are in early infection. The firms announced this week that they are enrolling uninfected people who live with someone who is COVID-19 positive in a new Phase 3 trial to test the small molecule’s ability to prevent SARS-CoV-2 infection.
Pfizer has been extremely aggressive in trying to protect the details of its international COVID19 vaccine agreements. However, one of their contracts has allegedly leaked.
